NeoGenomics to Leverage Thermo Fisher Sequencing Solution in Myeloid Cancer Study
NeoGenomics will use Thermo Fisher Scientific’s next-generation sequencing solution in a pharma-sponsored Phase 1 study of myeloid cancer.
Read MorePosted by Andy Lundin | Dec 28, 2021 | Cancer, Sequencing Systems |
NeoGenomics will use Thermo Fisher Scientific’s next-generation sequencing solution in a pharma-sponsored Phase 1 study of myeloid cancer.
Read MorePosted by Chris Wolski | Dec 24, 2021 | Dementias & Alzheimer’s |
New approaches and technologies are providing an array of tools to identify Alzheimer’s disease in its earliest stages.
Read MorePosted by Andy Lundin | Dec 23, 2021 | Covid 19, Immunoassay Reagents & test Kits |
Thermo Fisher Scientific revealed an update to its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to enable direct detection of the Omicron variant.
Read MorePosted by Chris Wolski | Dec 20, 2021 | Sequencing Systems |
Genapsys CEO Jason Myers explains how his company is planning to solve return on investment and patient access with the company’s NGS platform.
Read MorePosted by Andy Lundin | Dec 17, 2021 | Covid 19, Immunoassay Reagents & test Kits |
Early batches of COVID-19 tests from the CDC exhibited false positive reactivity of negative controls due to flaws in the design and components of assays.
Read More